Catalogue

Background
GFAP (55 kD) is selectively located in astrocytes and represents the major constituent of astrocytic intermediate filaments. GFAP expression levels are highly variable during development of the central nervous system. In adults, GFAP levels increase as a result of the prolifeRation of astrocytes that occurs in a response to a variety of physical, chemical and etiological insults, including Alzheimer’s disease, epilepsy and multiple sclerosis. In the peripheral nervous system GFAP is expressed by Schwann cells. Upon differentiation, myelin forming Schwann cells down-regulate GFAP, whereas in non-myelin forming Schwann cells GFAP persists into adulthood.

Source
K39 is a rabbit polyclonal antiserum derived by immunization of a rabbit with a glial fibrillary acidic protein preparation from human spinal cord.

Product
Each vial contains 100 ul Rabbit polyclonal Serum containing 0.09% sodium azide.

Formulation: Each vial contains 100 ul Rabbit polyclonal Serum containing 0.09% sodium azide.

Specificity
K39 reacts exclusively with glial fibrillary acidic protein which is present in astrocytes in the central nervous system and Schwann cells.

Applications
K39 is suitable for immunoblotting, immunocytochemistry on permeabilized cells and immunohistochemistry on frozen and paraffin-embedded tissues. Optimal antibody dilution should be determined by titration; recommended range is 1:100 – 1:200 for immunohistochemistry with avidin-biotinylated Horseradish peroxidase complex (ABC) as detection reagent, and 1:100 – 1:1000 for immunoblotting applications.

Storage
The antibody is shipped at ambient temperature and may be stored at +4°C. For prolonged storage prepare appropriate aliquots and store at or below -20°C. Prior to use, an aliquot is thawed slowly in the dark at ambient temperature, spun down again and used to prepare working dilutions by adding sterile phosphate buffered saline (PBS, pH 7.2). Repeated thawing and freezing should be avoided. Working dilutions should be stored at +4°C, not refrozen, and preferably used the same day. If a slight precipitation occurs upon storage, this should be removed by centrifugation. It will not affect the performance or the concentration of the product.

Caution
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but Nordic-MUbio​ accepts no liability for any inaccuracies or omissions in this information.

References
1. Ramaekers, F. C., Puts, J. J., Moesker, O., Kant, A., Huysmans, A., Haag, D., Jap, P. H., Herman, C. J., and Vooijs, G. P. (1983). Antibodies to intermediate filament proteins in the immunohistochemical identification of Human tumours: an overview, Histochem J 15, 691-713. 2. Herpers, M. J., Ramaekers, F. C., Aldeweireldt, J., Moesker, O., and Slooff, J. (1986). Co-expression of glial fibrillary acidic protein- and vimentin-type intermediate filaments in Human astrocytomas, Acta Neuropathol 70, 333-9.

Protein Reference(s)

Database Name: UniProt

Accession Number: P14136

Safety Datasheet(s) for this product: